文献速递鼻科

慢性鼻窦炎伴鼻息肉患者鼻窦支架置入时机及短期临床疗效评估

[Evaluation of timing and short-term clinical efficacy of sinus stent implantation in chronic rhinosinusitis with nasal polyps].
PubMed 文献 · Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi · 2025-01-01

该随机对照研究纳入114例慢性鼻窦炎伴鼻息肉患者,随机分为对照组、术中支架组和术后支架组,最终86例纳入分析。结果显示糖皮质激素鼻窦支架置入可有效控制术后炎症、促进黏膜上皮化并降低术后干预率,术后2周置入支架在疗效稳定性和减少结痂方面优于术中置入。

要点

  • 糖皮质激素鼻窦支架置入可有效控制筛窦术区炎症,促进黏膜上皮化并降低术后干预率。
  • 术后2周置入支架简单易行,在疗效稳定性和减少结痂/凝结物形成方面优于术中置入。
  • 术中与术后支架组在鼻塞、流涕及内镜评分方面均较对照组有显著改善。

核心结论

  • 糖皮质激素鼻窦支架在筛窦区的置入能有效控制术区炎症,促进黏膜上皮化并降低术后干预率。
  • 术后2周置入支架简单易行,调整支架置入时机能够减少干痂形成并最大限度地发挥糖皮质激素疗效,有助于术腔的良性转归。

研究设计与样本

  • 采用G-power 3.1.9.7软件计算最小样本量,于2021年3月至2023年5月在武汉大学人民医院耳鼻咽喉头颈外科纳入符合标准的全组慢性鼻窦炎伴鼻息肉患者114例。
  • 患者随机分为对照组、术中支架组和术后支架组,术中支架组于内镜鼻窦手术中置入鼻窦药物支架,术后支架组于内镜鼻窦手术后2周常规清理术腔后置入支架,置入部位均为双侧筛窦,对照组仅接受内镜鼻窦手术及术后常规术腔清理。
  • 所有受试者于术后2、4、8及12周行随访评估,采集鼻部症状视觉模拟量表评分及鼻内镜评估筛窦术后恢复状况,应用GraphPad Prism 9进行统计学分析,计量资料采用方差分析,计数资料采用卡方检验。

主要发现

  • 114例中排除失访21例及术后口服糖皮质激素干预7例,最终86例纳入分析,其中男45例、女41例,年龄18~65岁,对照组29例、术中支架组29例、术后支架组28例。
  • 术后4周,术中支架组和术后支架组的鼻塞和流涕评分较对照组显著改善(P<0.05);术后8周,术后支架组在鼻塞和流涕评分上持续优于对照组(P值均<0.05),术中支架组仅在鼻塞评分上有统计学差异(P<0.05)。
  • 各组间头面部闷胀感、嗅觉减退及鼻腔干燥/结痂感评分差异无统计学意义(P值均>0.05)。
  • 术后2周,术中支架组筛窦结痂评分高于对照组和术后支架组(P<0.05);支架置入后2周,术后支架组结痂/凝结物评分显著低于术中支架组(P<0.001)。
  • 术中支架组术后4周囊泡及息肉样变发生率较对照组显著降低(P<0.05),术后支架组在术后4、8、12周均低于对照组(P值均<0.05);术后8周及12周术后支架组筛窦黏膜上皮化率明显高于对照组;术中支架组术后8周和12周干预率低于对照组(P<0.05),术后支架组在支架置入后所有随访时间点干预率显著低于对照组(P<0.05);术中、术后支架组并发症发生率显著低于对照组(P<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To assess the optimal timing and short-term clinical efficacy of sinus drug-eluting stent placement in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Methods: The minimum sample size was calculated using G-power 3.1.9.7 software. From March 2021 and May 2023, a total of 114 eligible patients with CRSwNP were recruited in this study at the Department of Otolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University. The patients were randomly assigned to three groups: the control group, the intraoperative stent group, and the postoperative stent group. In the intraoperative stent group, drug-eluting stents were implanted during endoscopic sinus surgery (ESS), while patients in the postoperative stent group received drug-eluting stent 2 weeks after ESS, following routine debridement of the surgical cavity. Bilateral ethmoid sinus stenting was performed for both stent groups, while the control group only underwent ESS with standard postoperative cavity debridement. All subjects were followed up at 2, 4, 8, and 12 weeks postoperatively. Nasal symptom Visual Analog Scale (VAS) scores and endoscopic evaluations of the ethmoid cavity-assessing obstruction, crusting, polypoid mucosal changes, epithelialization of ethmoid cavity, need for intervention, and complications such as middle turbinate lateralization and adhesions-were collected to evaluate the treatment efficacy of three groups. Statistical analyses were performed using GraphPad Prism 9. Analysis of variance (ANOVA) was applied to analyze continuous variables among the three groups, and chi-square tests were used for categorical variables. Results: Among 114 CRSwNP patients, 21 lost follow-up patients and 7 postoperative oral corticosteroid intervention patients were excluded. Finally, 86 patients were included in the analysis, including 45 males and 41 females, aged 18-65 years. The cohort comprised 29 in the control group, 29 in the intraoperative stent group, and 28 in the postoperative stent group. Successful bilateral ethmoid sinus stent implantation was achieved in both stent groups. At 4 weeks postoperatively, compared with the control group, both stent groups showed significant improvements in nasal congestion and rhinorrhea scores (P<0.05). At 8 weeks, the postoperative group continued to demonstrate superior outcomes in these two symptoms (both P<0.05), while the intraoperative group only showed significant improvement in nasal congestion (P<0.05). No significant differences were observed in facial pressure, olfactory loss, or nasal dryness scores among the three groups (all P>0.05). Endoscopic evaluation revealed that both stent groups had significant improvements in ethmoid sinus obstruction scores at 4 weeks compared with the control group, with the postoperative group maintaining this advantage at 8 weeks (P<0.05). At 2 weeks, the intraoperative stent group had higher crusting scores than other groups (P<0.05). At 2 weeks after stent implantation, the postoperative stent group had significantly lower crusting scores than the intraoperative stent group (P<0.001). The intraoperative group had a significantly lower incidence of ethmoid sinus edema and polypoid changes at 4 weeks compared with the control group (P<0.05), while the postoperative group showed reduced rates of these pathological changes at 4, 8, and 12 weeks (all P<0.05). The postoperative stent group had significantly higher rates of ethmoid sinus mucosal epithelialization at 8 and 12 weeks postoperatively compared with the control group. The intraoperative stent group required fewer interventions than the control group at both 8 and 12 weeks, while the postoperative stent group maintained lower interventions rates at all follow-up points after implantation (all P<0.05). Additionally, the incidence of complications was significantly lower in both stent groups compared with the control group (P<0.05). Overall, stent implantation at different time points showed similar efficacy, with the postoperative group demonstrating more stable outcomes and less crusting/coagulation formation compared with the intraoperative group. Conclusions: The implantation of corticosteroid sinus stents in the ethmoid sinuses effectively controls postoperative inflammation, promotes mucosal epithelialization, and reduces postoperative intervention rates. Stent implantation two weeks after surgery is feasible. Adjusting the timing of stent placement can minimize crust formation and maximize the corticosteroid effect, thereby facilitating a benign course of the surgical site. 目的: 评估全组慢性鼻窦炎伴鼻息肉(CRSwNP)患者筛窦置入鼻窦药物支架的最佳时机及短期临床疗效。 方法: 采用G-power 3.1.9.7软件计算最小样本量。于2021年3月至2023年5月期间,在武汉大学人民医院耳鼻咽喉头颈外科共纳入符合标准的全组CRSwNP患者114例。将患者随机分为对照组、术中支架组和术后支架组。术中支架组患者于内镜鼻窦手术(ESS)中置入鼻窦药物支架,而术后支架组患者则在ESS后2周进行常规清理术腔后,再置入鼻窦药物支架,支架置入部位均在双侧筛窦;对照组接受ESS及术后常规术腔清理。所有受试者于术后2、4、8及12周行随访评估。采集患者的鼻部症状视觉模拟量表评分,通过鼻内镜检查对筛窦术后恢复状况进行评估,评估指标包括筛窦腔阻塞和结痂、囊泡或黏膜息肉样变、黏膜上皮化水平、中鼻甲外移、筛窦腔粘连情况等。应用GraphPad Prism 9进行统计学分析,内镜评分等计量资料采用方差分析,上皮化率及术后干预率等计数资料采用卡方检验。 结果: 114例CRSwNP患者中,排除失访患者21例及术后口服糖皮质激素干预者7例,最终将86例患者纳入分析,其中男45例,女41例,年龄18~65岁;包括对照组29例、术中支架组29例,以及术后支架组28例。术中及术后支架组患者的双侧筛窦均成功置入支架。术后4周,术中、术后支架组的鼻塞和流涕评分较对照组显著改善(P<0.05);术后8周,相较于对照组,术后支架组在鼻塞和流涕评分上持续表现出显著优势(P值均<0.05),术中支架组仅在鼻塞评分上存在有统计学意义的差异(P<0.05)。各组间头面部闷胀感、嗅觉减退及鼻腔干燥/结痂感评分的差异无统计学意义(P值均>0.05)。鼻内镜评估显示:术后4周,术中和术后支架组筛窦阻塞评分较对照组显著改善;术后8周,术后支架组与对照组相比表现出持续优势(P<0.05)。术后2周,术中支架组筛窦结痂评分高于对照组和术后支架组(P<0.05);支架置入后2周,术后支架组的结痂/凝结物评分显著低于术中支架组(P<0.001)。术中支架组的术后4周囊泡及息肉样变发生率较对照组显著降低(P<0.05);术后支架组的囊泡及息肉样变发生率则在术后4、8、12周均低于对照组(P值均<0.05)。术后8周及12周,术后支架组的筛窦黏膜上皮化率明显高于对照组。术中支架组术后8周和12周的干预率低于对照组(P<0.05);在支架置入后的所有随访时间点,术后支架组所需的干预率显著低于对照组(P<0.05)。术中、术后支架组的并发症(如中鼻甲外移和术腔粘连)发生率显著低于对照组(P<0.05)。不同时机置入鼻窦支架对CRSwNP患者的疗效相似,术后支架置入在疗效稳定性和减少术腔结痂/凝结物形成方面优于术中支架置入。 结论: 糖皮质激素鼻窦支架在筛窦区的置入能有效控制术区炎症,促进黏膜上皮化并降低术后干预率。术后2周置入支架简单易行,调整支架置入时机能够减少干痂形成并最大限度地发挥糖皮质激素疗效,有助于术腔的良性转归。.

来源:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhou HQ, Tan L, Liu PQ, et al. [Evaluation of timing and short-term clinical efficacy of sinus stent implantation in chronic rhinosinusitis with nasal polyps]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025. PMID: 40692229. doi:10.3760/cma.j.cn115330-20250425-00252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。